Annovis Bio, Inc.
ANVS
$1.24
-$0.07-5.00%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.65% | -34.16% | -33.21% | -19.16% | -0.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 108.77% | 64.20% | 11.24% | -12.10% | -42.08% |
| Operating Income | -108.77% | -64.20% | -11.24% | 12.10% | 42.08% |
| Income Before Tax | -63.66% | -40.82% | -17.34% | 39.22% | 29.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.66% | -40.82% | -17.34% | 39.22% | 29.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.66% | -40.82% | -17.34% | 39.22% | 29.66% |
| EBIT | -108.77% | -64.20% | -11.24% | 12.10% | 42.08% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 12.54% | 21.10% | 28.46% | 61.91% | 53.89% |
| Normalized Basic EPS | 12.71% | 21.26% | 28.47% | 61.91% | 53.89% |
| EPS Diluted | 14.59% | 22.98% | 46.64% | 65.98% | 58.43% |
| Normalized Diluted EPS | 12.71% | 21.26% | 28.40% | 61.89% | 53.87% |
| Average Basic Shares Outstanding | 73.71% | 66.82% | 68.74% | 57.02% | 55.83% |
| Average Diluted Shares Outstanding | 73.71% | 66.82% | 68.05% | 56.32% | 55.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |